Why is APBD Misdiagnosed as MS or ALS? Key Differences
At a Glance
Adult Polyglucosan Body Disease (APBD) is often misdiagnosed as MS or ALS because it shares symptoms like leg stiffness and bladder issues, along with similar white matter changes on MRIs. A correct APBD diagnosis requires specialized GBE1 genetic testing to distinguish it from these conditions.
In this answer
4 sections
Adult Polyglucosan Body Disease (APBD) is frequently mistaken for Multiple Sclerosis (MS) or Amyotrophic Lateral Sclerosis (ALS) because it shares the same core symptoms—such as leg stiffness and bladder issues—and similar abnormalities on brain imaging [1]. Because APBD is a rare genetic disorder, neurologists naturally suspect common diseases like MS or ALS first. It often takes years of ruling out these conditions and dealing with incorrect treatments before specialized testing correctly identifies APBD [1].
Symptom Overlap: The Clinical Mimic
APBD typically begins in adulthood with a specific trio of symptoms: progressive spastic paraparesis (increasing leg stiffness and weakness), neurogenic bladder (loss of bladder control causing urinary urgency or incontinence), and peripheral neuropathy (nerve damage in the lower legs causing numbness or tingling) [2][3].
- Why it looks like MS: Primary Progressive MS commonly causes the exact same combination of progressive leg stiffness and bladder dysfunction as its first symptoms [1].
- Why it looks like ALS: ALS involves the degeneration of upper motor neurons (causing spasticity and brisk reflexes) and lower motor neurons (causing muscle weakness and wasting). The combination of APBD’s upper motor neuron signs (stiff legs) and peripheral nerve damage closely mimics the progressive motor decline seen in ALS or Primary Lateral Sclerosis (PLS) [4]. However, ALS typically does not cause sensory numbness or bladder issues. In APBD, severe motor weakness often drives the initial suspicion of ALS, but the presence of sensory and bladder symptoms eventually prompts doctors to reconsider their diagnosis and look further.
MRI Overlap: White Matter Changes
Brain scans are usually what lead a neurologist toward a misdiagnosis of MS. An MRI of a patient with APBD typically shows leukoencephalopathy—abnormal changes or damage in the brain’s white matter [1][5].
In APBD, abnormal glycogen (polyglucosan bodies) accumulates in the brain’s support cells (astrocytes) and neurons [6][7]. On an MRI, this damage appears as bright spots (hyperintensities) in the periventricular regions (areas around the brain’s fluid-filled spaces) and the brainstem [3][1]. Because MS also causes bright spots in these exact same regions due to demyelination (loss of the protective coating on nerves), radiologists frequently interpret the APBD scan as MS [1][6].
Another overlapping MRI finding is spinal cord atrophy (shrinking of the spinal cord), which is seen in both MS and APBD [1]. However, shrinking of the upper spinal cord (cervical spine) and the lower brainstem (medulla) is a nearly universal feature in APBD [3]. This consistent shrinking can be a key clue for an expert radiologist differentiating between the diseases.
Reaching the Right Diagnosis
This clinical and imaging overlap is why the APBD diagnostic journey is often long and deeply frustrating [8][1]. It validates why so many patients spend years with an MS or ALS label before finding the truth.
The key to finally distinguishing APBD from MS or ALS is specialized testing. While a lumbar puncture (spinal tap) in MS often shows specific inflammatory markers called oligoclonal bands, these are absent in APBD. Instead of relying only on symptoms and imaging, a definitive diagnosis requires genetic testing to look for mutations in the GBE1 gene [3]. If genetic testing is inconclusive, doctors can also measure the activity of the glycogen branching enzyme in a blood sample, or perform a skin or nerve biopsy to physically look for the abnormal polyglucosan bodies under a microscope.
What Happens After an APBD Diagnosis?
After finally receiving an accurate diagnosis, you will need to transition your care. While you may continue seeing a general neurologist, it is highly recommended to involve specialists familiar with rare genetic or metabolic disorders (such as a neurogeneticist).
Because APBD is an inherited condition, genetic counseling is essential to help you understand what this diagnosis means for your siblings, children, and extended family members.
Although there is currently no cure for APBD, a multi-disciplinary care team can actively manage your symptoms. This team typically includes physical therapists to help with mobility and leg stiffness, and urologists to manage bladder function and preserve kidney health. Finding rare disease support groups or patient registries can also connect you with a community that understands this unique diagnostic journey.
Common questions in this guide
Why do APBD symptoms mimic Multiple Sclerosis (MS)?
How is APBD different from ALS?
What tests can confirm an APBD diagnosis instead of MS?
Should I see a specialist if I suspect my MS or ALS is actually APBD?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Could my specific combination of leg stiffness, bladder issues, and sensory numbness be explained by a genetic condition like APBD rather than ALS?
- 2.Does my MRI show specific patterns of white matter changes or cervical spinal cord atrophy that are more characteristic of a leukodystrophy than MS?
- 3.Should we order a genetic panel for adult-onset leukodystrophies before settling on a diagnosis of MS?
- 4.Who can you refer me to for genetic counseling to help my family understand their risks for inheriting APBD?
- 5.What specialists should I add to my care team to actively manage my bladder and mobility symptoms?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (8)
- 1
Frequent misdiagnosis of adult polyglucosan body disease.
Hellmann MA, Kakhlon O, Landau EH, et al.
Journal of neurology 2015; (262(10)):2346-51 doi:10.1007/s00415-015-7859-4.
PMID: 26194201 - 2
Adult polyglucosan body disease presenting as a unilateral progressive plexopathy.
Naddaf E, Kassardjian CD, Kurt YG, et al.
Muscle & nerve 2016; (53(6)):976-81 doi:10.1002/mus.25041.
PMID: 26789422 - 3
Adult polyglucosan body disease: Natural History and Key Magnetic Resonance Imaging Findings.
Mochel F, Schiffmann R, Steenweg ME, et al.
Annals of neurology 2012; (72(3)):433-41 doi:10.1002/ana.23598.
PMID: 23034915 - 4
The Upper Motor Neuron-Improved Knowledge from ALS and Related Clinical Disorders.
Menon P, Vucic S
Brain sciences 2021; (11(8)) doi:10.3390/brainsci11080958.
PMID: 34439577 - 5
Adult polyglucosan body disease: an acute presentation leading to unmasking of this rare disorder.
Johal J, Castro Apolo R, Johnson MW, et al.
Hospital practice (1995) 2022; (50(3)):244-250 doi:10.1080/21548331.2021.1874182.
PMID: 33412965 - 6
GBE1-related disorders: Adult polyglucosan body disease and its neuromuscular phenotypes.
Souza PVS, Badia BML, Farias IB, et al.
Journal of inherited metabolic disease 2021; (44(3)):534-543 doi:10.1002/jimd.12325.
PMID: 33141444 - 7
AAV-Mediated Artificial miRNA Reduces Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.
Gumusgoz E, Kasiri S, Guisso DR, et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):982-993 doi:10.1007/s13311-022-01218-7.
PMID: 35347645 - 8
Case report: Expanding the understanding of the adult polyglucosan body disease continuum: novel presentations, diagnostic pitfalls, and clinical pearls.
Gayed MM, Sgobbi P, Pinto WBVR, et al.
Frontiers in genetics 2023; (14()):1282790 doi:10.3389/fgene.2023.1282790.
PMID: 38164512
This page is for informational purposes only and does not replace professional medical advice. Always consult your neurologist or a genetic specialist regarding your diagnosis and treatment options.
Get notified when new evidence is published on Glycogen Storage Disease Type IV.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.